A Phase 3 Double-Blind, Placebo Controlled, Parallel Group Study Of A Disease Modifying Agent In Subjects With Early Parkinson Disease
Posted Date: May 15, 2019
- Investigator: Alok Sahay
- Type of Study: Drug
The purpose of this study is to determine if an investigational drug called isradipine is safe and helpful in slowing the rate of PD decline. Isradipine has been approved by the Food and Drug Administration (FDA) to treat high blood pressure but is considered investigational in this study, as it ha
Criteria:
You Are Being Asked To Take Part In This Research Study Because You Have Been Diagnosed With Parkins
Keywords:
Sahay, Early Stages Of Park, Newly Diagnosed, Isradipine, Parkinson's Disease
For More Information:
Hilary Perez
(513) 558-0112
hilary.perez@uc.edu